Overview

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

Status:
Recruiting

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if doctors can use the results of special tests of subjects tumor tissue, that will look for specific abnormalities in the tumor, to choose a specific drug that is targeted to work against that abnormality (called molecular profiling) and to see what effects (good and/or bad) that targeted drug has on subjects cancer when it is given with standard chemotherapy.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Chicago

Collaborator:

Amgen

Treatments:

Antibodies
Ramucirumab
Trastuzumab